Sanofi-aventis and Regeneron expand strategic Antibody Collaboration
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.
Original Source of Sanofi-aventis and Regeneron expand strategic Antibody Collaboration
